Med Page Today

JANUARY 14, 2025

(MedPage Today) -- Medical experts from around the globe proposed a more nuanced approach to diagnosing obesity that does not rely exclusively on body mass index (BMI) alone. Writing in The Lancet Diabetes & Endocrinology, the global commission.

Obesity 93

Obesity BMI Diabetes 93

Cardiovascular Diabetology

FEBRUARY 11, 2024

Heart failure (HF) is increasing at an alarming rate, primary due to the rising in aging, obesity and diabetes. Notably, individuals with type 1 diabetes (T1D) face a significantly elevated risk of HF, leading.

Heart Failure 111

Heart Failure Diabetes Obesity 111

Science Daily - Heart Disease

SEPTEMBER 13, 2024

Babies born to pregnant women with obesity are more likely to develop heart problems and diabetes as adults due to fetal damage caused by the high-fat, high-energy diet of their mother.

Diet 121

Diet Diabetes Cardiovascular Disease Obesity 121

HCPLive

JANUARY 3, 2025

A systematic review and meta-analysis of observational real-world data finds nearly half of patients who begin a GLP-1 RA will discontinue within a year.

Obesity 111

Obesity Diabetes 111

Cardiometabolic Health Congress

JANUARY 3, 2024

In today’s society, the prevalence of obesity has become a significant concern. have obesity, and this rate has increased by more than 10 percentage points in the past two decades. Understanding the prevalence of obesity is crucial in comprehending why events like Healthy Weight Week are essential. of adults in the U.S.

Obesity 97

Obesity Diabetes Blood Pressure BMI 97

Science Daily - Heart Disease

JANUARY 17, 2024

Young adults who reported higher stress as adolescents were more likely to have high blood pressure, obesity and other cardiometabolic risk factors as adults, finds new study.

Blood Pressure 100

Blood Pressure Obesity Risk Factors Diabetes 100

HCPLive

JUNE 23, 2024

In the special on-site ADA 2024 episode, hosts are joined by the ADA's Chief Scientific and Medical Officer Robert Gabbay, MD, PhD, to discuss the newly formed Obesity Association.

Obesity 83

Obesity Diabetes 83

Med Page Today

OCTOBER 29, 2024

(MedPage Today) -- SAN DIEGO -- Semaglutide (Wegovy) reduced albuminuria in patients with overweight or obesity and chronic kidney disease (CKD) but without type 2 diabetes, a randomized trial showed. Among 101 patients, those who received 2.

Diabetes 95

Diabetes Kidney Disease Obesity 95

HCPLive

DECEMBER 22, 2024

In this episode, hosts discuss the efficacy of MariTide for obesity, a head-to-head comparison of semaglutide vs. tirzepatide, and concerns about GLP-1 agonist compounding.

Diabetes 115

Diabetes Obesity 115

Dr. Paddy Barrett

MAY 24, 2024

In the US, over 45% of the population has either diabetes or pre-diabetes 1. The absolute majority of those with diabetes have type 2 diabetes, which is usually associated with excess visceral fat and poor cardiometabolic health. Because a diagnosis of diabetes is very likely to shorten your life. Pre-Diabetes.

Diabetes 98

Diabetes Diet BMI Exercise 98

HCPLive

DECEMBER 19, 2023

Weight cycling could lead to a relative loss of fat-free mass in people living with overweight and obesity at high risk of type 2 diabetes.

Diabetes 105

Diabetes Obesity 105

Medical Xpress - Cardiology

JANUARY 17, 2024

Young adults who reported higher stress during their teenage years to adulthood were more likely to have high blood pressure, obesity and other cardiometabolic risk factors than their peers who reported less stress, according to new research published in the Journal of the American Heart Association.

Blood Pressure 92

Blood Pressure Obesity Risk Factors Diabetes 92

Med Page Today

MAY 11, 2024

(MedPage Today) -- NEW ORLEANS -- A "culturally sensitive" exercise intervention led to weight loss and other benefits in African-American women with obesity at risk for diabetes, researchers reported. The program tested in the ongoing, single.

Obesity 82

Obesity Exercise Diabetes Research 82

American College of Cardiology

APRIL 6, 2024

The goal of the STEP-HFpEF DM trial was to compare the safety and efficacy of semaglutide among patients with obesity-related heart failure with preserved ejection fraction (HFpEF) and type 2 diabetes mellitus (DM).

Preserved Ejection Fraction 68

Preserved Ejection Fraction Heart Failure Obesity Diabetes 68

Cardiovascular Diabetology

SEPTEMBER 11, 2024

Cardiovascular disease represents a significant risk factor for mortality in individuals with type 2 diabetes mellitus (T2DM). High-density lipoprotein (HDL) is believed to play a crucial role in maintaining c.

Obesity 130

Obesity Risk Factors Cardiovascular Disease Diabetes 130

HCPLive

JANUARY 21, 2025

of commercially insured individuals with obesity, but not diabetes, initiated semaglutide within 6 months of diagnosis. Approximately 2.0%

Obesity 59

Obesity Diabetes 59

Med Page Today

DECEMBER 4, 2024

(MedPage Today) -- In part one of this three-part Instagram Live discussion, MedPage Today editor-in-chief Jeremy Faust, MD, talks about how GLP-1 receptor agonists are transforming diabetes and obesity care in a discussion with Karl Nadolsky.

Obesity 52

Obesity Diabetes 52

Med Page Today

APRIL 7, 2024

(MedPage Today) -- ATLANTA -- Weight loss and heart failure benefits with semaglutide (Wegovy) extended to patients with obesity-related heart failure with preserved ejection fraction (HFpEF) who have type 2 diabetes, the STEP-HFpEF DM trial showed.

Preserved Ejection Fraction 74

Preserved Ejection Fraction Diabetes Heart Failure Obesity 74

Med Page Today

JUNE 7, 2024

(MedPage Today) -- For people with obesity and diabetes, bariatric metabolic surgery was associated with a greater reduction in mortality compared with first-generation GLP-1 receptor agonists if the individuals had their diabetes for a decade.

Obesity 111

Obesity Diabetes 111

Becker's Hospital Review - Cardiology

AUGUST 27, 2024

22 in Diabetes, Obesity and Metabolism: A Journal of Pharmacology and Therapeutics. GLP-1s reduced mortality and complications from cardiovascular events, according to a study published Aug.

Pharmacology 113

Pharmacology Obesity Diabetes 113

Science Daily - Heart Disease

SEPTEMBER 23, 2024

With Medicare now covering semaglutide for people with obesity and cardiovascular disease who don't have diabetes, a study looks at who that might include, depending on what cutoffs prescription plans apply.

Medicare 114

Medicare Obesity Cardiovascular Disease Diabetes 114

Dr. Paddy Barrett

OCTOBER 11, 2024

Obesity is one of the world’s biggest health crisis and only seems to be getting worse. For over 50 years, the rates of obesity have continued to rise worldwide 1. The most recent data on obesity has shown a decline for the first time in a very long time. Between 2020 and 2023, the rates of obesity dropped by about 2% 2.

Obesity 68

Obesity Dementia Cancer Coronary Artery Disease 68

American College of Cardiology

JANUARY 8, 2024

Obesity is a multifaceted disease that is directly and indirectly implicated in atherosclerotic cardiovascular disease (CVD), heart failure (HF), atrial fibrillation (AF), and multiple CVD risk factors, including dyslipidemia, hypertension, type 2 diabetes mellitus (DM), and sleep disorders.

Obesity 70

Obesity Atrial Fibrillation Risk Factors Heart Failure 70

Frontiers in Cardiovascular Medicine

JANUARY 5, 2025

Obesity is one of the major global health concerns of the 21st century, associated with many comorbidities such as type 2 diabetes mellitus (T2DM), metabolic dysfunction-associated steatotic liver disease, and early and aggressive atherosclerotic cardiovascular disease, which is the leading cause of death worldwide.

Obesity 52

Obesity Atherosclerosis Cardiovascular Disease Diabetes 52

Med Page Today

DECEMBER 19, 2024

(MedPage Today) -- The shortage of the diabetes and obesity injectable tirzepatide (Mounjaro, Zepbound) has been resolved, the FDA announced Thursday. As a result, compounders will have a grace period of 60 to 90 days to wrap up production and.

Obesity 110

Obesity Diabetes 110

American College of Cardiology

APRIL 10, 2024

What are the effects of semaglutide across a broad range of outcomes in people with obesity-related heart failure with preserved ejection fraction (HFpEF) with and without diabetes, and consistency across key patient subgroups?

Preserved Ejection Fraction 56

Preserved Ejection Fraction Obesity Heart Failure Diabetes 56

Cardiovascular Diabetology

JUNE 28, 2024

The atherogenic index of plasma (AIP) is closely associated with the onset of diabetes, with obesity being a significant risk factor for type 2 diabetes mellitus (T2DM). However, the association between the AI.

Obesity 52

Obesity Diabetes Risk Factors Research 52

American Heart News - Heart News

NOVEMBER 11, 2024

Research Highlights: Heart disease, Type 2 diabetes, high blood pressure and obesity were more common and linked to reduced access to healthy food among people who lived in neighborhoods previously subjected to structural racism-based policies that.

Heart Disease 106

Heart Disease Blood Pressure Obesity Diabetes 106

The British Journal of Cardiology

OCTOBER 8, 2024

Sodium-glucose cotransporter type 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists are established glucose-lowering and weight-lowering agents used in the management of type 2 diabetes mellitus and obesity.

Obesity 40

Obesity Diabetes Kidney Disease Heart Failure 40

HCPLive

JANUARY 13, 2025

Hosts are joined by a registered dietitian and practicing endocrinologist to discuss dietitians' role in managing patients receiving incretin therapies.

Obesity 69

Obesity Diabetes 69

CardiacWire

DECEMBER 6, 2023

The already massive GLP-1 obesity drug segment might have gained a major future competitor last week, following Roche’s acquisition of weight loss biotech Carmot Therapeutics. The biotech also has a once-daily dual GLP-1/GIP injectable (yes, daily) that’s in Phase 2 trials and would treat obese or overweight patients with type 1 diabetes.

Obesity 59

Obesity Diabetes 59

Medical Xpress - Cardiology

JANUARY 9, 2025

For overweight or obese individuals without diabetes, but with pre-existing cardiovascular disease, semaglutide (Ozempic, Wegovy) is not cost-effective at current pricing, new research shows. However, with price reductions or rebates up to 50%, it could meet the benchmark for value in health care.

Diabetes 59

Diabetes Obesity Cardiovascular Disease Research 59

American Heart News - Heart News

NOVEMBER 11, 2023

Research Highlights: In a large, international clinical trial, people with obesity or overweight but not diabetes taking semaglutide for more than 3 years had a 20% lower risk of heart attack, stroke or death due to cardiovascular disease and lost an.

Obesity 52

Obesity Diabetes Heart attacks Heart Attack 52

Science Daily - Heart Disease

NOVEMBER 20, 2024

Weight-loss and diabetes drug tirzepatide can reduce the risk of death or worsening heart failure for patients with obesity and heart failure with preserved pump function, new research reveals.

Heart Failure 99

Heart Failure Obesity Diabetes Research 99

HCPLive

OCTOBER 30, 2024

A decade after bariatric surgery, most teens maintained weight loss and reduced obesity-related conditions such as type 2 diabetes and hypertension.

Obesity 59

Obesity Hypertension Diabetes 59

CardiacWire

MAY 8, 2024

Officially published by the AHA six months ago, CKM syndrome defines the connections and risks associated with obesity, type 2 diabetes, chronic kidney disease, and cardiovascular disease. Stage 2 (metabolic risk factors like hypertension, diabetes, CKD) – 49% Stage 3 (kidney disease or high cardiovascular risks) – 5.4%

Kidney Disease 116

Kidney Disease Obesity Risk Factors Diabetes 116

American College of Cardiology

DECEMBER 23, 2024

The goal of the SURMOUNT-1 trial was to assess the efficacy and safety of tirzepatide, a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist versus placebo in overweight or obese adults without diabetes.

Obesity 54

Obesity Diabetes Article 54